Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
P/B ratio for Scilex Holding Company (SCLX)
P/B ratio as of 2023: -1.54
According to Scilex Holding Company's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.54. At the end of 2022 the company had a P/B ratio of 14.78.
P/B ratio history for Scilex Holding Company from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -1.54 |
| 2022 | 14.78 |
| 2021 | -5.96 |
| 2020 | -9.81 |
| 2019 | 0.00 |